Retatrutide

Overview

Retatrutide (LY3437943) is a novel investigational peptide developed by Eli Lilly and Company that functions as a triple agonist at three distinct incretin and metabolic hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and the glucagon receptor. This triple-receptor engagement represents a significant advancement over dual agonists such as tirzepatide (GLP-1/GIP) and single agonists like semaglutide (GLP-1 only), potentially offering superior efficacy for weight management and metabolic disease.

The peptide is a 39-amino acid synthetic compound engineered through systematic structure-activity relationship studies to achieve balanced agonism across all three target receptors. Its design incorporates a C20 fatty diacid moiety conjugated via a linker to enable albumin binding, which extends the plasma half-life to approximately 6 days, allowing once-weekly subcutaneous dosing. This pharmacokinetic profile is critical for patient compliance in chronic disease management.

Retatrutide entered clinical development with Phase 1 trials in 2021 and rapidly progressed through Phase 2, generating substantial attention in the obesity and endocrinology research communities for the magnitude of weight loss reported in Phase 2 data. The peptide is currently in Phase 3 clinical trials for obesity and type 2 diabetes, with regulatory submissions anticipated in the coming years.

Mechanism of Action

Retatrutide’s mechanism of action is rooted in the simultaneous activation of three complementary metabolic pathways, each contributing distinct physiological effects that synergize to produce robust improvements in body weight and metabolic parameters.

GLP-1 Receptor Agonism

Activation of the GLP-1 receptor, expressed in pancreatic beta cells, the central nervous system, and the gastrointestinal tract, promotes glucose-dependent insulin secretion, suppresses glucagon release, delays gastric emptying, and reduces appetite through hypothalamic satiety signaling. GLP-1 receptor engagement is the best-characterized component, shared with established agents like semaglutide and liraglutide, and contributes significantly to both glycemic control and weight reduction.

GIP Receptor Agonism

The GIP receptor, expressed on pancreatic islet cells, adipose tissue, and bone, plays a complex role in energy homeostasis. GIP receptor activation enhances insulin secretion, modulates lipid metabolism in adipocytes, and appears to potentiate the weight loss effects of GLP-1 agonism through mechanisms that are still being elucidated. Research by Campbell and Drucker (2013), published in Cell Metabolism, demonstrated that GIP signaling in the CNS may independently reduce food intake, complementing GLP-1-mediated satiety.

Glucagon Receptor Agonism

The inclusion of glucagon receptor agonism is the distinguishing feature of Retatrutide. Glucagon, traditionally viewed as a counter-regulatory hormone that raises blood glucose, also has potent effects on energy expenditure and lipid metabolism. Glucagon receptor activation in the liver stimulates glycogenolysis and gluconeogenesis, but critically, it also increases hepatic fatty acid oxidation and thermogenesis. Habegger et al. (2010), writing in Nature Reviews Endocrinology, highlighted glucagon’s ability to increase resting energy expenditure by 150-200 kcal/day, which can meaningfully augment the caloric deficit achieved through appetite suppression alone.

Research Summary

Phase 2 Clinical Trial (2023)

The landmark Phase 2 clinical trial results were published by Jastreboff et al. (2023) in the New England Journal of Medicine. This 48-week, randomized, double-blind, placebo-controlled study enrolled 338 adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity. Participants receiving the highest dose of Retatrutide (12 mg weekly) achieved a mean body weight reduction of 24.2% from baseline, compared to 2.1% in the placebo group. This magnitude of weight loss exceeded that reported for any other anti-obesity medication in clinical trials at the time of publication, including tirzepatide (approximately 20-22%) and semaglutide (approximately 15-17%).

Type 2 Diabetes Efficacy

Rosenstock et al. (2023) published results from a parallel Phase 2 trial in patients with type 2 diabetes in The Lancet. Over 36 weeks, Retatrutide demonstrated dose-dependent reductions in HbA1c, with the 12 mg dose achieving a mean reduction of 2.02 percentage points from a baseline of approximately 8.3%. Body weight decreased by up to 16.9% in the diabetes cohort. Notably, 71% of participants in the highest dose group achieved an HbA1c below 5.7%, essentially entering the normoglycemic range, a result that surpassed outcomes seen with existing GLP-1 and dual-agonist therapies.

Hepatic and Cardiovascular Effects

Secondary analyses from the Phase 2 program revealed significant improvements in cardiometabolic risk factors. Retatrutide treatment produced mean reductions in triglycerides of 28-35%, decreases in systolic blood pressure of 4-8 mmHg, and improvements in liver fat content as assessed by imaging biomarkers. The reduction in hepatic steatosis was particularly notable, with exploratory MRI data suggesting reductions in liver fat fraction exceeding 50% in some dose groups, generating interest in Retatrutide as a potential treatment for metabolic dysfunction-associated steatotic liver disease (MASLD).

Safety and Tolerability

The most common adverse events were gastrointestinal in nature, consistent with the class effects of incretin-based therapies: nausea (reported in 16-45% of participants depending on dose), diarrhea, vomiting, and decreased appetite. These events were generally mild to moderate in severity and declined over time with dose titration. No significant safety signals related to pancreatic, thyroid, or cardiovascular events were identified, though long-term safety monitoring continues in the Phase 3 program.

Dosing in Published Research

Retatrutide is an investigational drug and is not approved by any regulatory agency, so it has no labeled dose. The doses that appear in the literature are those used in its clinical trial program. In the published Phase 2 obesity trial (NEJM, 2023; ClinicalTrials.gov NCT04881760), participants received once-weekly subcutaneous retatrutide at one of four target doses, alongside dose-escalation regimens:

• 1 mg once weekly.
• 4 mg once weekly.
• 8 mg once weekly.
• 12 mg once weekly.

These figures describe what was administered to subjects in that specific trial, identified above.

Safety and Side Effects

Retatrutide is an investigational drug, and its safety profile is still being defined in ongoing clinical trials. The most common adverse effects reported to date are gastrointestinal, including nausea, vomiting, and diarrhea, and are dose-related, consistent with its GLP-1 receptor activity. Dose-related increases in heart rate have been observed. As a member of the incretin-based drug class, retatrutide would be expected to share the class concerns: in rodent studies, GLP-1 receptor agonists have caused thyroid C-cell tumors, and the approved drugs in this class carry an FDA boxed warning and contraindications related to medullary thyroid carcinoma and Multiple Endocrine Neoplasia syndrome type 2. Because retatrutide is not approved, its labeling, contraindications, and full risk profile have not been finalized, and longer-term safety data are not yet available. Material sold as retatrutide outside clinical trials is unregulated and of uncertain identity, dose, and purity.

Current Research Status

Retatrutide (LY3437943) is an investigational triple agonist of the GIP, GLP-1, and glucagon receptors, developed by Eli Lilly. As of 2026 it is in Phase 3 clinical trials and is not approved by the FDA or any other regulatory agency for any use. It should be regarded as an experimental compound; any retatrutide obtained outside a clinical trial is unapproved.

Further reading: Retatrutide Dosing: Titration Schedules and the Pen Format reviews the titration schedules used in clinical trials and how the investigational pen format is dosed.

Frequently Asked Questions